| Metric | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|
| Research and development | $11.1M-64.2% | $31.0M+604.7% | $4.4M | — |
| General and administrative | $15.0M-33.3% | $22.5M+407.5% | $4.4M+365.8% | $953K |
| Total operating expenses | $26.1M-51.2% | $53.6M+505.7% | $8.8M+1027.8% | -$953K |
| Loss from operations | -$26.1M+51.2% | -$53.6M-505.7% | -$8.8M | — |
| Interest expense, net | -$196K-6.3% | -$184K+84.7% | -$1.2M | — |
| Merger transaction costs | -$7.5M | — | — | — |
| Change in fair value of warrants | $61K+204.3% | -$58K | — | $413K |
| Change in fair value of convertible promissory notes | $48.5M | — | -$50.4M | — |
| Loss on issuance of commitment shares | -$890K | — | — | — |
| Net loss | -$26.3M-91.4% | -$13.7M+77.3% | -$60.5M-1471.9% | $4.4M |
| Net loss attributable to common stockholders, basic | -$26.8M-161.1% | -$10.3M+83.0% | -$60.5M | — |
| Net loss attributable to common stockholders, diluted | -$26.8M-161.1% | -$10.3M+83.0% | -$60.5M | — |
| Net loss per share attributable to common stockholders, basic | -$8.08-130.9% | -$3.50-43.4% | -$2.44-2811.1% | $0.09 |
| Net loss per share attributable to common stockholders, diluted | -$8.08-130.9% | -$3.50-43.4% | -$2.44-2811.1% | $0.09 |
| Weighted-average common stock outstanding, basic | $3.3M+13.2% | $2.9M-88.1% | $24.8M-28.3% | $34.5M |
| Weighted-average common stock outstanding, diluted | $3.3M+13.2% | $2.9M-88.1% | $24.8M-28.3% | $34.5M |
Source: SEC EDGAR XBRL. % change vs prior period shown where available.
Source: SEC EDGAR 10-K and 10-Q filings. Up to 10 years annual / 16 quarters shown.